Orfiril Long (Sodium Valproate)

Sodium Valproate, the active ingredient in Orfiril Long, is a carboxylate anticonvulsant presented as an extended‑release tablet for oral use. It is employed to manage seizure disorders, mood stabilization in bipolar disorder, and migraine prevention in adult patients.

GNH USA supplies Orfiril Long as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orfiril Long, a carboxylate anticonvulsant, is used in several neurological and psychiatric conditions. - Epilepsy: reduces the frequency and severity of generalized and focal seizures. - Bipolar disorder: helps stabilize mood and prevents manic episodes. - Migraine prophylaxis: decreases the number of migraine attacks and their intensity.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea or gastrointestinal upset - Weight gain or increased appetite - Tremor or mild motor incoordination - Dizziness or drowsiness

Serious or Rare Side Effects: - Hepatotoxicity, including severe liver injury - Pancreatitis, presenting with abdominal pain - Severe skin reactions such as Stevens‑Johnson syndrome - Thrombocytopenia or other blood dyscrasias - Hyperammonemia leading to encephalopathy - Fatal or life‑threatening overdose effects

Before initiating therapy, clinicians should consider several safety measures. - Liver monitoring: perform baseline and periodic liver function tests. - Blood count surveillance: check platelet levels and complete blood count regularly. - Pregnancy risk: avoid use in pregnancy unless benefits outweigh risks, due to teratogenic potential. - Hepatic disease: use with caution in patients with existing liver impairment. - Renal adjustment: dose may need modification in severe renal dysfunction. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Sodium valproate can alter the pharmacokinetics of several concomitant medicines.

Major Interactions (Avoid): - Carbamazepine, phenytoin, phenobarbital: potent enzyme inducers that reduce valproate levels. - Other valproate formulations: risk of additive toxicity and overdose. - Aspirin or other NSAIDs: increase risk of bleeding complications.

Moderate Interactions (Monitor Closely): - Lamotrigine: requires dose adjustment to avoid severe skin reactions. - Oral contraceptives: valproate may reduce contraceptive efficacy, necessitating additional barrier methods.